By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Exact Sciences climbed almost 16 percent today after investment firm Rodman & Renshaw upgraded its stock to Market Outperform from Perform.

Rodman & Renshaw also increased the 18-month price target on Exact Sciences' shares to $12 from $7. Shares of the company on Nasdaq closed at $7.46.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.